ALT 8-K 2026-09-29
Altimmune, Inc. (ALT) 8-K dated 2026-09-29 — accession 0001326190-26-000056.
Altimmune, Inc. (ALT) is a biotechnology company listed on US.
Altimmune, Inc. filed a 8-K on 2026-09-29. Accession 0001326190-26-000056.
This 8-K covers: Director/officer change (Item 5.02). SEC EDGAR holds the official filing and its exhibits.
Latest reported ALT revenue for 2025-12-31 was $41.0K. Net income was -$88.1M. Revenue was up 105.0% from 2024-12-31 to 2025-12-31. ALT currently screens at market cap $527.0M.
Not investment advice. The ALT SEC hub lists recent forms. The stock page is the research view.